View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsValens 향후 성장Future 기준 점검 2/6핵심 정보113.4%이익 성장률115.80%EPS 성장률Pharmaceuticals 이익 성장21.7%매출 성장률55.2%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트n/a최근 향후 성장 업데이트Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 8 analysts covering Valens expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$5.59m in 2022. Average annual earnings growth of 75% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updates공시 • Jan 19+ 1 more updateSNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining 91.9% stake in The Valens Company Inc. (TSX:VLNS).SNDL Inc. (NasdaqCM:SNDL) entered into an arrangement agreement to acquire remaining 91.9% stake in The Valens Company Inc. (TSX:VLNS) for CAD 94.2 million on August 22, 2022. Under the terms of the Agreement, Valens' shareholders will receive, for each Valens Share, 0.3334 of a common share of SNDL. The combined company will operate as SNDL Inc., and Valens shareholders will own approximately 9.5% of the pro forma entity. The Agreement provides for, among other things, customary support and non-solicitation covenants from Valens, including customary "fiduciary out" provisions that allow Valens to accept a superior proposal in certain circumstances and a five-business day "right to match period" in favour of SNDL. The Agreement also provides for the payment of a termination fee of CAD 8 million payable to SNDL by Valens in the event the Transaction is terminated in certain specified circumstances. The Transaction will be carried out by way of a court-approved plan of arrangement under the Canada Business Corporations Act. The implementation of the Transaction will be subject to the approval of at least two thirds of the Valens Shares entitled to be voted by Valens shareholders and the approval of a simple majority of the Valens Shares entitled to be voted by Valens shareholders, other than Valens shareholders required to be excluded under applicable laws, at a special meeting expected to be convened by Valens by the end of November 2022 (the "Meeting"), Shares to be issued pursuant to the Arrangement shall have been approved for listing on Nasdaq, and the receipt of applicable orders from the Ontario Superior Court of Justice and applicable regulatory approvals, including under the Competition Act (Canada) and the applicable provincial liquor and cannabis regulators. Valens' board of directors has unanimously approved the Transaction after receiving the unanimous recommendation of a special committee of Valens directors (the "Special Committee"). Valens' board of directors has unanimously resolved to recommend that the shareholders of Valens vote in favour of the Transaction. SNDL’s Board of Directors also unanimously approved the Transaction. All directors and executive officers of Valens have entered into voting support agreements with SNDL pursuant to which, among other things, the parties have agreed to vote their Valens Shares in favour of the Transaction. The shareholders meeting of Valens is scheduled on November 29, 2022. As of November 22, 2022, both Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) have recommended that Valens shareholders (the “Valens Shareholders”) vote in favour of the arrangement. On November 29, 2022, shareholders of Valens approved the transaction. As of December 13, 2022, The Valens Company has been granted additional 180 calendar day grace period by Nasdaq to regain compliance with Minimum Bid Price rule. As a result of the extension, The Valens Company now has until June 12, 2023, to regain compliance with the Bid Price Requirement. The Ontario Superior Court of Justice (Commercial List) has granted a final order approving the transaction. The transaction is expected to close during January 2023. Together with incremental revenues from greater distribution of Valens products, it is estimated that the Transaction will deliver upwards of CAD 15 million of additional EBITDA on an annual run-rate basis through synergies and other strategic initiatives. Cormark Securities Inc. has provided a fairness opinion to the Special Committee of Valens that, subject to the assumptions, limitations and qualifications set out in such fairness opinion, the consideration to be received by Valens shareholders pursuant to the Transaction is fair from a financial point of view to Valens' shareholders. ATB Capital Markets Inc. is acting as financial advisor to SNDL. Ranjeev Dhillon and Rami Chalabi of McCarthy Tétrault LLP acting as legal counsels to SNDL. Cormark Securities Inc. is acting as financial advisor and Donald Belovich of Stikeman Elliott LLP is acting as legal counsel to Valens. Laurel Hill Advisory Group, LLC acted as information agent with a service fee of $50,000 (CAD 67,869) and Computershare Investor Services Inc. acted transfer agent to Valens. Marcum LLP acted as accountant while Odyssey Trust Company acted as transfer agent to SNDL. SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining 91.9% stake in The Valens Company Inc. (TSX:VLNS) on January 17, 2023. Frank Krasovec has been appointed to the Board of Directors of SNDL, effective January 17, 2023. The Board now consists of six directors. Zach George will continue to serve as Chief Executive Officer of SNDL and Tyler Robson, the former CEO of Valens, will join the leadership team as President of Cannabis. Andrew Stordeur, SNDL's former President and Chief Operating Officer has left the company effective January 13, 2023. Immediately prior to the effective date of the Transaction, SNDL owned an aggregate of 6.5 million Valens Shares, representing approximately 8.1% of the outstanding Valens Shares at such time. Following the closing of the Transaction, there are 260.7 million SNDL Shares outstanding, with existing SNDL Shareholders holding approximately 89.4% of such outstanding SNDL Shares and former Valens Shareholders holding approximately 10.6% of such outstanding SNDL Shares. The Valens Shares are expected to be delisted from the Toronto Stock Exchange.Reported Earnings • Jul 15Second quarter 2022 earnings released: CA$2.13 loss per share (vs CA$0.17 loss in 2Q 2021)Second quarter 2022 results: CA$2.13 loss per share (down from CA$0.17 loss in 2Q 2021). Revenue: CA$24.0m (up 28% from 2Q 2021). Net loss: CA$160.8m (loss widened CA$152.1m from 2Q 2021). Over the next year, revenue is forecast to grow 66%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 16 percentage points per year, which is a significant difference in performance.Recent Insider Transactions • Apr 27Independent Director recently bought €98k worth of stockOn the 21st of April, Andrew Cockwell bought around 90k shares on-market at roughly €1.09 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €7.0m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Apr 21Independent Director recently bought €70k worth of stockOn the 19th of April, Guy Beaudin bought around 65k shares on-market at roughly €1.08 per share. In the last 3 months, there was an even bigger purchase from another insider worth €91k. Insiders have collectively bought €6.9m more in shares than they have sold in the last 12 months.Reported Earnings • Apr 15First quarter 2022 earnings released: CA$0.38 loss per share (vs CA$0.14 loss in 1Q 2021)First quarter 2022 results: CA$0.38 loss per share (down from CA$0.14 loss in 1Q 2021). Revenue: CA$23.2m (up 16% from 1Q 2021). Net loss: CA$25.7m (loss widened 319% from 1Q 2021). Over the next year, revenue is forecast to grow 71%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.Recent Insider Transactions • Apr 08Independent Director recently bought €91k worth of stockOn the 5th of April, Andrew Cockwell bought around 47k shares on-market at roughly €1.95 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €6.7m more in shares than they have sold in the last 12 months.Reported Earnings • Mar 02Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: CA$0.88 loss per share (down from CA$0.49 loss in FY 2020). Revenue: CA$78.2m (down 6.7% from FY 2020). Net loss: CA$49.0m (loss widened 137% from FY 2020). Revenue missed analyst estimates by 3.3%. Over the next year, revenue is forecast to grow 78%, compared to a 7.8% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.Recent Insider Transactions • Oct 21CEO & Chairman recently bought €80k worth of stockOn the 18th of October, Andrew Robson bought around 59k shares on-market at roughly €1.35 per share. This was the largest purchase by an insider in the last 3 months. Andrew has been a buyer over the last 12 months, purchasing a net total of €193k worth in shares.Reported Earnings • Oct 14Third quarter 2021 earnings released: CA$0.076 loss per share (vs CA$0.024 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CA$21.0m (up 16% from 3Q 2020). Net loss: CA$12.8m (loss widened 318% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 8 analysts covering Valens expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$5.59m in 2022. Average annual earnings growth of 75% is required to achieve expected profit on schedule.Recent Insider Transactions • Aug 11Insider recently sold €75k worth of stockOn the 5th of August, Paolo Pero sold around 43k shares on-market at roughly €1.74 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €6.7m more than they sold in the last 12 months.Executive Departure • Jun 01Independent Director has left the companyOn the 25th of May, Nitin Kaushal's tenure as Independent Director ended after 2.7 years in the role. As of March 2021, Nitin personally held 60.00k shares (€104k worth at the time). A total of 4 executives have left over the last 12 months.Executive Departure • May 19Chief Financial Officer has left the companyOn the 17th of May, Christopher Buysen's tenure as Chief Financial Officer ended after 2.9 years in the role. As of December 2020, Christopher personally held 333.17k shares (€355k worth at the time). A total of 3 executives have left over the last 12 months.Recent Insider Transactions • Oct 30CEO & Chairman recently bought €66k worth of stockOn the 28th of October, Andrew Robson bought around 71k shares on-market at roughly €0.93 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Andrew has been a net seller over the last 12 months, reducing personal holdings by €909k.Is New 90 Day High Low • Oct 29New 90-day low: €0.92The company is down 30% from its price of €1.31 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.68 per share.Is New 90 Day High Low • Oct 06New 90-day low: €0.97The company is down 35% from its price of €1.50 on 08 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €25.61 per share.Is New 90 Day High Low • Sep 18New 90-day low: €1.22The company is down 25% from its price of €1.63 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.97 per share.공시 • Jul 07The Valens Company Inc. to Report Q2, 2020 Results on Jul 15, 2020The Valens Company Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Jul 15, 2020이익 및 매출 성장 예측DB:7LV0 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CAD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수11/30/2023172-21N/AN/A211/30/2022107-219N/AN/A28/31/202286-236-72-65N/A5/31/202287-221-81-72N/A2/28/202281-69-80-70N/A11/30/202178-49-64-47N/A8/31/202176-44-48-31N/A5/31/202173-35-45-21N/A2/28/202172-29-41-15N/A11/30/202084-21-47-16N/A8/31/2020980-53-21N/A5/31/2020979-37-12N/A2/29/2020882-37-5N/A11/30/201958-7-28-8N/A8/31/201927-18-25-8N/A5/31/201911-27-29-13N/A2/28/20192-19-17-11N/A11/30/20180-16-14-9N/A8/31/20180-9-11-6N/A5/31/20180-8-9-5N/A2/28/20180-7-4-2N/A11/30/20170-4-3-2N/A8/31/20170-11-2-1N/A5/31/20170-11-1-1N/A2/28/20170-9-1-1N/A11/30/20160-800N/A8/31/20160-100N/A5/31/20160-1N/A0N/A2/29/20160-1N/A0N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 7LV0 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: 7LV0 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: 7LV0 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: 7LV0 의 수익(연간 55.2%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 7LV0 의 수익(연간 55.2%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 7LV0의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/01/19 01:09종가2023/01/17 00:00수익2022/08/31연간 수익2021/11/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스The Valens Company Inc.는 7명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David KideckelATB CormarkKimberly Thompson-HedlinCanaccord GenuityJohn ChuDesjardins Securities Inc.4명의 분석가 더 보기
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 8 analysts covering Valens expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$5.59m in 2022. Average annual earnings growth of 75% is required to achieve expected profit on schedule.
공시 • Jan 19+ 1 more updateSNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining 91.9% stake in The Valens Company Inc. (TSX:VLNS).SNDL Inc. (NasdaqCM:SNDL) entered into an arrangement agreement to acquire remaining 91.9% stake in The Valens Company Inc. (TSX:VLNS) for CAD 94.2 million on August 22, 2022. Under the terms of the Agreement, Valens' shareholders will receive, for each Valens Share, 0.3334 of a common share of SNDL. The combined company will operate as SNDL Inc., and Valens shareholders will own approximately 9.5% of the pro forma entity. The Agreement provides for, among other things, customary support and non-solicitation covenants from Valens, including customary "fiduciary out" provisions that allow Valens to accept a superior proposal in certain circumstances and a five-business day "right to match period" in favour of SNDL. The Agreement also provides for the payment of a termination fee of CAD 8 million payable to SNDL by Valens in the event the Transaction is terminated in certain specified circumstances. The Transaction will be carried out by way of a court-approved plan of arrangement under the Canada Business Corporations Act. The implementation of the Transaction will be subject to the approval of at least two thirds of the Valens Shares entitled to be voted by Valens shareholders and the approval of a simple majority of the Valens Shares entitled to be voted by Valens shareholders, other than Valens shareholders required to be excluded under applicable laws, at a special meeting expected to be convened by Valens by the end of November 2022 (the "Meeting"), Shares to be issued pursuant to the Arrangement shall have been approved for listing on Nasdaq, and the receipt of applicable orders from the Ontario Superior Court of Justice and applicable regulatory approvals, including under the Competition Act (Canada) and the applicable provincial liquor and cannabis regulators. Valens' board of directors has unanimously approved the Transaction after receiving the unanimous recommendation of a special committee of Valens directors (the "Special Committee"). Valens' board of directors has unanimously resolved to recommend that the shareholders of Valens vote in favour of the Transaction. SNDL’s Board of Directors also unanimously approved the Transaction. All directors and executive officers of Valens have entered into voting support agreements with SNDL pursuant to which, among other things, the parties have agreed to vote their Valens Shares in favour of the Transaction. The shareholders meeting of Valens is scheduled on November 29, 2022. As of November 22, 2022, both Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) have recommended that Valens shareholders (the “Valens Shareholders”) vote in favour of the arrangement. On November 29, 2022, shareholders of Valens approved the transaction. As of December 13, 2022, The Valens Company has been granted additional 180 calendar day grace period by Nasdaq to regain compliance with Minimum Bid Price rule. As a result of the extension, The Valens Company now has until June 12, 2023, to regain compliance with the Bid Price Requirement. The Ontario Superior Court of Justice (Commercial List) has granted a final order approving the transaction. The transaction is expected to close during January 2023. Together with incremental revenues from greater distribution of Valens products, it is estimated that the Transaction will deliver upwards of CAD 15 million of additional EBITDA on an annual run-rate basis through synergies and other strategic initiatives. Cormark Securities Inc. has provided a fairness opinion to the Special Committee of Valens that, subject to the assumptions, limitations and qualifications set out in such fairness opinion, the consideration to be received by Valens shareholders pursuant to the Transaction is fair from a financial point of view to Valens' shareholders. ATB Capital Markets Inc. is acting as financial advisor to SNDL. Ranjeev Dhillon and Rami Chalabi of McCarthy Tétrault LLP acting as legal counsels to SNDL. Cormark Securities Inc. is acting as financial advisor and Donald Belovich of Stikeman Elliott LLP is acting as legal counsel to Valens. Laurel Hill Advisory Group, LLC acted as information agent with a service fee of $50,000 (CAD 67,869) and Computershare Investor Services Inc. acted transfer agent to Valens. Marcum LLP acted as accountant while Odyssey Trust Company acted as transfer agent to SNDL. SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining 91.9% stake in The Valens Company Inc. (TSX:VLNS) on January 17, 2023. Frank Krasovec has been appointed to the Board of Directors of SNDL, effective January 17, 2023. The Board now consists of six directors. Zach George will continue to serve as Chief Executive Officer of SNDL and Tyler Robson, the former CEO of Valens, will join the leadership team as President of Cannabis. Andrew Stordeur, SNDL's former President and Chief Operating Officer has left the company effective January 13, 2023. Immediately prior to the effective date of the Transaction, SNDL owned an aggregate of 6.5 million Valens Shares, representing approximately 8.1% of the outstanding Valens Shares at such time. Following the closing of the Transaction, there are 260.7 million SNDL Shares outstanding, with existing SNDL Shareholders holding approximately 89.4% of such outstanding SNDL Shares and former Valens Shareholders holding approximately 10.6% of such outstanding SNDL Shares. The Valens Shares are expected to be delisted from the Toronto Stock Exchange.
Reported Earnings • Jul 15Second quarter 2022 earnings released: CA$2.13 loss per share (vs CA$0.17 loss in 2Q 2021)Second quarter 2022 results: CA$2.13 loss per share (down from CA$0.17 loss in 2Q 2021). Revenue: CA$24.0m (up 28% from 2Q 2021). Net loss: CA$160.8m (loss widened CA$152.1m from 2Q 2021). Over the next year, revenue is forecast to grow 66%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 16 percentage points per year, which is a significant difference in performance.
Recent Insider Transactions • Apr 27Independent Director recently bought €98k worth of stockOn the 21st of April, Andrew Cockwell bought around 90k shares on-market at roughly €1.09 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €7.0m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Apr 21Independent Director recently bought €70k worth of stockOn the 19th of April, Guy Beaudin bought around 65k shares on-market at roughly €1.08 per share. In the last 3 months, there was an even bigger purchase from another insider worth €91k. Insiders have collectively bought €6.9m more in shares than they have sold in the last 12 months.
Reported Earnings • Apr 15First quarter 2022 earnings released: CA$0.38 loss per share (vs CA$0.14 loss in 1Q 2021)First quarter 2022 results: CA$0.38 loss per share (down from CA$0.14 loss in 1Q 2021). Revenue: CA$23.2m (up 16% from 1Q 2021). Net loss: CA$25.7m (loss widened 319% from 1Q 2021). Over the next year, revenue is forecast to grow 71%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.
Recent Insider Transactions • Apr 08Independent Director recently bought €91k worth of stockOn the 5th of April, Andrew Cockwell bought around 47k shares on-market at roughly €1.95 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €6.7m more in shares than they have sold in the last 12 months.
Reported Earnings • Mar 02Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: CA$0.88 loss per share (down from CA$0.49 loss in FY 2020). Revenue: CA$78.2m (down 6.7% from FY 2020). Net loss: CA$49.0m (loss widened 137% from FY 2020). Revenue missed analyst estimates by 3.3%. Over the next year, revenue is forecast to grow 78%, compared to a 7.8% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
Recent Insider Transactions • Oct 21CEO & Chairman recently bought €80k worth of stockOn the 18th of October, Andrew Robson bought around 59k shares on-market at roughly €1.35 per share. This was the largest purchase by an insider in the last 3 months. Andrew has been a buyer over the last 12 months, purchasing a net total of €193k worth in shares.
Reported Earnings • Oct 14Third quarter 2021 earnings released: CA$0.076 loss per share (vs CA$0.024 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CA$21.0m (up 16% from 3Q 2020). Net loss: CA$12.8m (loss widened 318% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 8 analysts covering Valens expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$5.59m in 2022. Average annual earnings growth of 75% is required to achieve expected profit on schedule.
Recent Insider Transactions • Aug 11Insider recently sold €75k worth of stockOn the 5th of August, Paolo Pero sold around 43k shares on-market at roughly €1.74 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €6.7m more than they sold in the last 12 months.
Executive Departure • Jun 01Independent Director has left the companyOn the 25th of May, Nitin Kaushal's tenure as Independent Director ended after 2.7 years in the role. As of March 2021, Nitin personally held 60.00k shares (€104k worth at the time). A total of 4 executives have left over the last 12 months.
Executive Departure • May 19Chief Financial Officer has left the companyOn the 17th of May, Christopher Buysen's tenure as Chief Financial Officer ended after 2.9 years in the role. As of December 2020, Christopher personally held 333.17k shares (€355k worth at the time). A total of 3 executives have left over the last 12 months.
Recent Insider Transactions • Oct 30CEO & Chairman recently bought €66k worth of stockOn the 28th of October, Andrew Robson bought around 71k shares on-market at roughly €0.93 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Andrew has been a net seller over the last 12 months, reducing personal holdings by €909k.
Is New 90 Day High Low • Oct 29New 90-day low: €0.92The company is down 30% from its price of €1.31 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.68 per share.
Is New 90 Day High Low • Oct 06New 90-day low: €0.97The company is down 35% from its price of €1.50 on 08 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €25.61 per share.
Is New 90 Day High Low • Sep 18New 90-day low: €1.22The company is down 25% from its price of €1.63 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.97 per share.
공시 • Jul 07The Valens Company Inc. to Report Q2, 2020 Results on Jul 15, 2020The Valens Company Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Jul 15, 2020